Toleranzia
0,768 SEK -1,03 %Vær den første som følger denne virksomhed
Toleranzia is a research company focused on the development of drug candidates for the treatment of autoimmune diseases. The company has developed a platform technology focused on the muscular disease myasthenia gravis. In addition, the technology has been used in other areas such as diabetes and multiple sclerosis. Research collaboration is done together with external partners within the field. The head office is based in Gothenburg.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
TOL
Daglig lav / høj pris
0,738 / 0,77
SEK
Markedsværdi
84,72 mio. SEK
Aktieomsætning
9,97 t SEK
Volumen
13 t
Finanskalender
Delårsrapport
25.08.2023
Delårsrapport
27.10.2023
Årsrapport
23.02.2024
Viser Alle indholdstyper